{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed\/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic\nLeukemia\/Lymphoma (T-ALL\/T-LBL)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-ii-study-of-daratumumab-hyaluronidase-for-chemotherapy-relapsed-refractory-minimal-residual-disease-mrd-in-t-cell-acute-lymphoblasticleukemia-lymphoma-t-all-t-lbl\/#breadcrumbitem"}]}